JPRN-jRCTs051230037招募中3 期
Randomized, multicenter, phase 3 study evaluating the efficacy of IMmunotherapy(Atezolizumab) Plus Anti-VEGF therapy(Bevacizumab) in Combination with Transarterial chemoembolization for unresectable HCC - IMPACT
Masatoshi KUDO0 个研究点目标入组 600 人开始时间: 2023年6月13日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1)Typical hepatocellular carcinoma confirmed by tissue and histological diagnosis or imaging diagnosis such as dynamic CT (MRI) and AASLD (the American Association for the Study of Liver Diseases) guidelines.
- •2)Unresectable hepatocellular carcinoma.
- •3)Barcelona-Clinic Liver Cancer (BCLC)-C (with or without EHS, Vp1-2 if there is vascular invasion) or BCLC A of a single tumour with a maximum size >= 5 cm considered by the responsible physician to be unsuitable for TACE.
- •4)>= 18 years of age at enrollment.
- •5)Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.
- •6)At least one intrahepatic target lesion according to RECIST ver.1.1.
- •7)At least one or more intrahepatic lesions with tumor staining and in which TACE can be performed.
- •8)No history of systemic therapy for hepatocellular carcinoma.
- •9)Child-Pugh class A within 14 days prior to enrollment.
- •10)Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days before enrollment.
- •If multiple test results are available during the concerned period, the results closest to enrollment will be used. Blood transfusion or hematopoietic factor administration within 30 days before the date of measurements is not permitted.
- •i.Neutrophil count: >= 1,000/mm^3
- •ii.Platelet count: >= 50,000/mm^3
- •iii.Aspartate aminotransferase (AST): <= 150U/L
- •iv.Alanine aminotransferase (ALT): (males) <= 210U/L, (females) <= 115U/L
- •v.Total bilirubin: <= 3.0 mg/dL
- •vi.Serum albumin: >= 2.8 g/dL
- •vii.Serum creatinine: (males) <= 1.605mg/dL, (females) <= 1.185mg/dL
- •viii.Urine protein: <= 2+
- •If >= 3+, urine protein / creatinine ratio: < 2.0 in spot urine (in case of 24-hour urine collection, urine protein < 2.0 g / 24 hr)
- •11)Personal written informed consent after the study has been fully explained.
排除标准
- •1) Patient is eligible for radical therapy (surgical resection, RFA) or radical TACE.
- •2) Vp3 or Vp4.
- •3) Total of hepatocellular carcinoma occupies more than 50% of the liver volume.
- •4) Patients who are difficult or at high risk for TACE and who meet the following criteria.
- •- Severe stenosis or obstruction of the hepatic artery detected by enhanced CT, MRI, or angiography.
- •- Severe arterial-portal or arterial-venous shunting.
- •- Moderate to severe intrahepatic bile duct dilatation.
- •- Previous duodenal papillotomy or biliopancreatic jejunostomy.
- •- Biliary stenting.
- •5) Current or recent (within 10 days before enrollment) use of full-dose oral or parenteral Antithrombotics or thrombolytic agents for therapeutic purposes (exclude prophylactic purpose).
- •6) Thrombosis or embolism within 180 days before enrollment.
- •7) Untreated or inadequately treated esophageal and/or gastric varices with, or at a high risk of, bleeding, or history of bleeding due to esophageal and/or gastric varices within 180 days pre-enrollment. EGD should be performed pre-enrollment to examine and preemptively treat varices of all sizes following local care standards. No need for re-examination if EGD performed within 180 days pre-enrollment confirmed the absence of varices.
- •8) Major surgical procedure within 28 days before enrollment (open chest, laparoscopy, thoracoscopic surgery, laparoscopic surgery and etc.); open biopsy or suturing for major trauma; or planned major surgical procedure during the study (open chest, laparoscopy).
- •9) Treatment with systemic immunostimulatory agents (interferon, interleukin-2 and etc.) within 180 days before enrollment.
- •10) Treatment with systemic immunosuppressive agents (corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, tumor necrosis factor [TNF]-alpha agents and etc.) within 14 days before enrollment, or anticipated need for systemic immunosuppressive agents during the study treatment, with the following exceptions: treatment with mineralocorticoids (fludrocortisone and etc.) or corticosteroids for chronic obstructive pulmonary disease (COPD), asthma or etc.
- •11) History within 180 days before enrollment or complication of autoimmune inflammatory disease.
- •However, the following shall be exceptions.
- •- The patient has autoimmune-related hypothyroidism and is using thyroid replacement hormone.
- •- Patients with type 1 diabetes controlled by insulin therapy.
- •- Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo vulgaris whose symptoms are limited to the skin only, if all of the following conditions are met (e.g., patients with psoriatic arthritis are eligible)
- •i) The rash covers less than 10% of the body surface area.
- •ii) Disease is well controlled at baseline and the only treatment required is a low potency topical corticosteroid.
- •iii) No acute exacerbation of the underlying disease within the past 12 months that requires solarene + UV-A irradiation, methotrexate, retinoids, biologics, oral calcineurin inhibitors, or potent or oral steroids.
- •12) History of active overlapping cancer or malignancy* (simultaneous overlapping cancer and metachronous overlapping cancer with a disease-free interval of 2 years or less).
- •* Following cancer is not defined as active overlapping cancer.
- •Prostate cancer in clinical stage I, laryngeal cancer with complete response to radiotherapy in clinical stage 0 or I, and completely resected cancers with a 5-year relative survival rate equal to or greater than 95%, such a
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the safety of 2 schedules of cabazitaxel (bi-weekly versus tri-weekly) plus prednisone in elderly men (= 70 years) with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen (CABASTY)Metastatic castration-resistant prostate cancer (mCRPC)EUCTR2016-001179-60-NLA.R.T.I.C (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie)170
已完成
3 期
Randomized multicenter, phase III trial evaluating the safety of 2 schedules of cabazitaxel (bi-weekly versus tri-weekly) plus prednisone in elderly men (= 65years) with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimeC61Malignant neoplasm of prostateDRKS00017467Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (ARTIC)Georges Pompidou European Hospital180
撤回
3 期
Randomized multicenter, phase III trial evaluating the safety of 2 schedules of cabazitaxel (bi-weekly versus tri-weekly) plus prednisone in elderly men (* 65 years) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen (CABASTY).Prostate cancerNL-OMON48773ARTIC20
进行中（未招募）
1 期
Evaluation of the safety of 2 schedules of cabazitaxel (bi-weekly versus tri-weekly) plus prednisone in elderly men (= 65 years) with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimeEUCTR2016-001179-60-DEA.R.T.I.C (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie)170
进行中（未招募）
不适用
A multicenter, phase III, randomized study to evaluate the efficacy of a response-adapted strategy to define maintenance after standard chemoimmunotherapy in patients with advanced-stage Follicular LymphomaPreviously untreated intermediate-high risk according to the FLIPI2 stage II-IV follicular lymphoma requiring therapeutic intervention.MedDRA version: 14.1Level: PTClassification code 10061170Term: Follicle centre lymphoma, follicular grade I, II, IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003170-60-ITFONDAZIONE ITALIANA LINFOMI ONLUS